BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24114056)

  • 1. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
    Carr JC; Sherman SK; Wang D; Dahdaleh FS; Bellizzi AM; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3(0 3):S739-S746. PubMed ID: 24114056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.
    Sherman SK; Maxwell JE; Carr JC; Wang D; Bellizzi AM; Sue O'Dorisio M; O'Dorisio TM; Howe JR
    Clin Exp Metastasis; 2014 Dec; 31(8):935-44. PubMed ID: 25241033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling.
    Carr JC; Boese EA; Spanheimer PM; Dahdaleh FS; Martin M; Calva D; Schafer B; Thole DM; Braun T; O'Dorisio TM; O'Dorisio MS; Howe JR
    Surgery; 2012 Dec; 152(6):998-1007. PubMed ID: 23158174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GIPR expression in gastric and duodenal neuroendocrine tumors.
    Sherman SK; Maxwell JE; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
    J Surg Res; 2014 Aug; 190(2):587-93. PubMed ID: 24565507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Pancreas as a Site of Metastasis or Second Primary in Patients with Small Bowel Neuroendocrine Tumors.
    Scott AT; Pelletier D; Maxwell JE; Sherman SK; Keck KJ; Li G; Dillon JS; O'Dorisio TM; Bellizzi AM; Howe JR
    Ann Surg Oncol; 2019 Aug; 26(8):2525-2532. PubMed ID: 31011904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
    Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
    Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors.
    Saller J; Seydafkan S; Shahid M; Gadara M; Cives M; Eschrich SA; Boulware D; Strosberg JR; Aejaz N; Coppola D
    Cancer Genomics Proteomics; 2019; 16(5):309-318. PubMed ID: 31467225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNAs associated with small bowel neuroendocrine tumours and their metastases.
    Miller HC; Frampton AE; Malczewska A; Ottaviani S; Stronach EA; Flora R; Kaemmerer D; Schwach G; Pfragner R; Faiz O; Kos-Kudła B; Hanna GB; Stebbing J; Castellano L; Frilling A
    Endocr Relat Cancer; 2016 Sep; 23(9):711-26. PubMed ID: 27353039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression.
    Choi S; Wang D; Chen X; Tang LH; Verma A; Chen Z; Kim BJ; Selesner L; Robzyk K; Zhang G; Pang S; Han T; Chan CS; Fahey TJ; Elemento O; Du YN
    Mol Cancer; 2019 May; 18(1):92. PubMed ID: 31072393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors.
    Scott AT; Weitz M; Breheny PJ; Ear PH; Darbro B; Brown BJ; Braun TA; Li G; Umesalma S; Kaemmer CA; Maharjan CK; Quelle DE; Bellizzi AM; Chandrasekharan C; Dillon JS; O'Dorisio TM; Howe JR
    Clin Cancer Res; 2020 Apr; 26(8):2011-2021. PubMed ID: 31937620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreastatin predicts survival in neuroendocrine tumors.
    Sherman SK; Maxwell JE; O'Dorisio MS; O'Dorisio TM; Howe JR
    Ann Surg Oncol; 2014 Sep; 21(9):2971-80. PubMed ID: 24752611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between Well-Differentiated Neuroendocrine Tumors and Ductal Adenocarcinomas of the Pancreas Assessed by Multi-Omics Profiling.
    Starzyńska T; Karczmarski J; Paziewska A; Kulecka M; Kuśnierz K; Żeber-Lubecka N; Ambrożkiewicz F; Mikula M; Kos-Kudła B; Ostrowski J
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32586046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in gene expression in small bowel neuroendocrine tumors associated with progression to metastases.
    Keck KJ; Breheny P; Braun TA; Darbro B; Li G; Dillon JS; Bellizzi AM; O'Dorisio TM; Howe JR
    Surgery; 2018 Jan; 163(1):232-239. PubMed ID: 29154080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP
    Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling.
    Tran CG; Scott AT; Li G; Sherman SK; Ear PH; Howe JR
    Surgery; 2021 Jan; 169(1):155-161. PubMed ID: 32611516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?
    Choi AB; Maxwell JE; Keck KJ; Bellizzi AJ; Dillon JS; OʼDorisio TM; Howe JR
    Pancreas; 2017 Oct; 46(9):1115-1120. PubMed ID: 28902780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NESP55, a novel chromogranin-like peptide, is expressed in endocrine tumours of the pancreas and adrenal medulla but not in ileal carcinoids.
    Jakobsen AM; Ahlman H; Kölby L; Abrahamsson J; Fischer-Colbrie R; Nilsson O
    Br J Cancer; 2003 Jun; 88(11):1746-54. PubMed ID: 12771991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.
    Sherman SK; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
    Surgery; 2013 Dec; 154(6):1206-13; discussion 1214. PubMed ID: 24238043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors.
    Richards-Taylor S; Tilley C; Jaynes E; Hu H; Armstrong T; Pearce NW; Plant R; Cave J
    Pancreas; 2017; 46(10):1354-1358. PubMed ID: 28984786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberration of ARID1A Is Associated With the Tumorigenesis and Prognosis of Sporadic Nonfunctional Pancreatic Neuroendocrine Tumors.
    Han X; Chen W; Chen P; Zhou W; Rong Y; Lv Y; Li JA; Ji Y; Chen W; Lou W; Xu X
    Pancreas; 2020 Apr; 49(4):514-523. PubMed ID: 32282764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.